AbbVie (ABBV) vs Novartis (NOVN)
AbbVie (ABBV) and Novartis (NOVN) side by side: both in Healthcare, listed on New York Stock Exchange and SIX Swiss Exchange. AbbVie is the larger of the two by approximate market capitalization (about 1.7×).
| Field | AbbVie | Novartis |
|---|---|---|
| Legal name | AbbVie Inc. | Novartis AG |
| Ticker | ABBV | NOVN |
| Exchange | New York Stock Exchange XNYS | SIX Swiss Exchange XSWX |
| Jurisdiction | United States | Switzerland |
| Sector | Healthcare | Healthcare |
| Industry | Pharmaceuticals | Pharmaceuticals |
| Market cap ≈ | $390bn | $230bn |
| Founded | 2013 | 1996 |
| Reporting currency | USD | CHF |
| LEI | FR5LCKFTG8054YNNRU85 | 5493007HIVTX6SY6XD66 |
| ISIN | US00287Y1091 | CH0012005267 |
| FIGI | BBG0025Y4RZ3 | BBG001SD31N7 |
| Index membership | S&P 500 | — |
| Held by (covered funds) | — | — |
AbbVie
Large pharmaceutical company spun off from Abbott in 2013, with immunology blockbusters Skyrizi and Rinvoq succeeding Humira, plus the Allergan aesthetics portfolio (Botox).
Novartis
Basel-based pharmaceutical company created by the 1996 merger of Ciba-Geigy and Sandoz, now a pure-play innovative-medicines business after spinning off Alcon and Sandoz. Key franchises include cardiovascular, oncology and immunology drugs.
Approximate reference values (seed-0.6 · 2026-08-29) — not real-time, not investment advice. Both sides as data: /api/v1/companies/abbvie · /api/v1/companies/novartis